Transient receptor potential cation channel subfamily V member 5 (TRPV5)
Homo sapiens — UniProt Q9NQA5
Data last refreshed: (UniProt release unknown)
Key facts
Transient receptor potential cation channel subfamily V member 5 (TRPV5) is a protein from Homo sapiens identified by UniProt accession Q9NQA5, 729 residues long. MolForge cross-references it against 1 known binders and 258 disease associations.
- UniProt accession: Q9NQA5; gene symbol TRPV5.
- Organism: Homo sapiens.
- Length: 729 amino acids.
- Target class: Ion channel.
- Approved drugs acting on it (DrugCentral): Gentamicin.
- Top disease associations (Open Targets): reticulocyte measurement, reticulocyte count and type 2 diabetes mellitus.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Transient receptor potential cation channel subfamily V member 5 |
|---|---|
| UniProt accession | Q9NQA5 |
| Gene | TRPV5 |
| Organism | Homo sapiens |
| Length | 729 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | Ion channel (inferred from UniProt keywords / EC) |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (1)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (258)
Diseases linked to this target (Open Targets).
- reticulocyte measurement · score 0.36
- reticulocyte count · score 0.30
- type 2 diabetes mellitus · score 0.24
- glioblastoma multiforme · score 0.18
- breast adenocarcinoma · score 0.16
- lung adenocarcinoma · score 0.12
- head and neck squamous cell carcinoma · score 0.12
- Dent disease · score 0.07
- nephrotic syndrome · score 0.07
- nephronophthisis · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9NQA5-F1 | alphafold | PREDICTED | 82.53 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9NQA5.
Amino-acid sequence (729 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target TRPV5?
DrugCentral lists 1 approved drug whose mechanism of action is TRPV5: Gentamicin.
Which diseases are associated with TRPV5?
The strongest Open Targets associations for TRPV5 are reticulocyte measurement, reticulocyte count, type 2 diabetes mellitus, glioblastoma multiforme and breast adenocarcinoma.
How long is the TRPV5 protein?
The Homo sapiens TRPV5 protein (UniProt Q9NQA5) is 729 amino acids long.
Browse: Targets: T · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9NQA5 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9NQA5 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.